Free Stock & ETF Comparisons

Compare Guardant Health and Foundation Medicine by liquid biopsy Shield colorectal cancer screening launch, tissue comprehensive genomic profiling revenue, reimbursement breadth, and which comprehensive genomic testing approach wins clinician adoption.

Compare XLV and IHI by diversified healthcare vs concentrated medtech exposure, pharma/biotech vs device/diagnostics weighting, expense ratio, and which healthcare equity ETF is right for an investor's portfolio position.

Compare Biohaven and Protagonist Therapeutics by CGRP migraine pipeline post-Pfizer acquisition revenue, iron deficiency drug rusfertide commercial launch, and which mid-stage specialty biotech has more near-term catalyst value.

Compare Veeva Systems and IQVIA by pharmaceutical CRM subscription ARR, clinical trial data analytics revenue, Vault R&D suite upsell, OCE (Veeva CRM replacement), and which life sciences technology platform is the more durable long-term compounder.

Compare Charles River Laboratories and Medpace Holdings by drug discovery outsourcing revenue, small/mid biotech CRO demand, COVID normalisation, and which contract research organisation is better managed through a biotech funding cycle.

Compare PerkinElmer and Bio-Techne by newborn screening instrument revenue, flow cytometry reagent ARR, COVID diagnostic normalisation, and which life science tool company has more durable growth from oncology and proteomics research.

Compare Align Technology (Invisalign) and SmileDirectClub's (legacy) business model by orthodontist channel vs DTC telehealth dentistry, gross margin premium, iTero scanner ecosystem lock-in, and which clear aligner approach is more scalable.

Compare STERIS and 3M by hospital sterile reprocessing service recurring revenue, health care segment earnings after PFAS litigation spin-off, and which healthcare products company has more predictable mid-cycle earnings.

Compare Bristol-Myers Squibb and Eli Lilly by Revlimid/Eliquis LOE impact vs Mounjaro/Zepbound obesity revenue, pipeline M&A strategy, dividend yield, and which large pharma stock is better positioned for the next five years.

Compare AbbVie and Merck by Skyrizi/Rinvoq Humira succession vs Keytruda patent cliff exposure, HIV and oncology pipeline depth, dividend growth, and which pharma giant is better prepared for the next decade of patent expirations.

Compare Edwards Lifesciences and NovaCure by transcatheter aortic valve (TAVR) market penetration, TTFields cancer therapy label expansion, structural heart disease TAM, and which medical device company has the more durable growth runway.

Compare Hill-Rom (now Baxter Welch Allyn) and Becton Dickinson by smart patient monitoring equipment ARR, Alaris infusion pump FDA recall resolution, diagnostics recurring consumable revenue, and which medtech turnaround is further along.

Compare Revance Therapeutics and Avient Corporation by DaxibotulinumtoxinA (DAXI) botulinum toxin market launch vs Botox/Dysport competition, and specialty polymer revenue for sustainable packaging, to highlight two very different speculative vs value investment cases.

Compare eHealth and GoHealth by Medicare Advantage plan enrollment, member retention, marketing cost per approved member, CMS commission regulation risk, and which Medicare insurance marketplace is closer to sustainable unit economics.

Compare Amarin and Docgo by Vascepa cardiovascular drug revenue sustainability post-generic entry, mobile health clinic government contract revenue, and which healthcare micro-cap is the better risk/reward proposition.

Compare Progyny and ACM Research by employer fertility benefits ARR, semiconductor wafer cleaning equipment revenue in China, TAM expansion, and which small/mid-cap growth company has more predictable near-term revenue.

Compare STAAR Surgical and Beam Therapeutics by EVO implantable collamer lens revenue growth vs base editing gene therapy clinical data, profitability timeline, and which medical innovation company is more suitable for growth-at-a-reasonable-price investors.

Compare Cross Country Healthcare and AMN Healthcare by travel nurse placement revenue normalisation, workforce solutions technology ARR, and which healthcare staffing company is better positioned as hospital labor markets normalise post-pandemic.

Compare Bausch & Lomb and Omnicell by contact lens and ophthalmic surgery revenue, hospital pharmacy robot dispensing ARR, and which healthcare product/automation company offers better earnings visibility through 2026.

Compare Phathom Pharmaceuticals and Arrowhead Pharmaceuticals by vonoprazan acid-related disease launch, RNAi liver-targeted therapy pipeline breadth, partnership revenue, and which specialty biotech is closer to self-sustaining cash flow.

Compare Sarepta Therapeutics and Summit Therapeutics by Elevidys Duchenne gene therapy revenue, ivonescimab lung cancer partnership (Summit/Akeso), regulatory timeline, and which rare disease biotech has higher near-term catalyst value.

Compare RxSight and Amphora by light adjustable intraocular lens post-cataract revenue ramp, specialty drug delivery device market, and which niche medical device company is capturing a new surgical standard of care.

Compare Glaukos and Amedisys by iDose sustained-release glaucoma drug delivery ARR, home health visit reimbursement, hospice admission growth, and which specialty healthcare company has more durable recurring revenue.

Compare Procept BioRobotics and Silk Road Medical by AquaBeam BPH robotic surgery adoption, TCAR carotid stenting device procedure growth, and which small-cap medical device company builds the more defensible clinical procedure moat.

Compare TransMedics and Butterfly Network by Organ Care System transport device revenue, handheld ultrasound probe subscription model, and which breakthrough medical device platform is on a faster path to hospital standard of care.

Compare Stevanato Group and Envista Holdings by pharmaceutical glass vial/syringe revenue, dental implant and orthodontic equipment market share, and which healthcare supplier delivers more consistent mid-cycle organic growth.

Compare ModivCare and Amphenol by NEMT Medicaid managed care contract revenue, high-speed connector revenue for AI data centers, and which services/industrials company has more predictable recurring mid-cycle revenue.

Compare PTC Therapeutics and TriplePoint Venture Growth by rare disease drug (Translarna/Upstaza) launch trajectory, venture lending BDC net investment income, and which smaller income/growth security is more suitable for an income-growth barbell portfolio.

Compare CareTrust REIT and Omega Healthcare Investors by skilled nursing and assisted living facility coverage ratio, dividend safety, acquisition pipeline, operator credit quality, and which healthcare REIT is better for income investors.

Compare NeoGenomics and Teladoc Health by oncology genomic testing volume, virtual primary and mental care ARPU, path to profitability, and which healthcare technology company has a more defensible recurring revenue model.

Compare Revolution Medicines and Kymera Therapeutics by KRAS G12C inhibitor revenue, RAS(ON) multi-selective program, targeted protein degradation IRAK4/STAT6 pipeline, and which oncology-focused biotech has higher near-term catalyst probability.

Compare Roivant Sciences and Merus by Vant subsidiary portfolio value, zunsemetinib pipeline milestones, Biclonics bispecific antibody platform clinical stage, and which platform biotech unlocks more near-term value for investors.

Compare Arcutis Biotherapeutics and Coherus BioSciences by Zoryve cream/foam dermatology launch trajectory, Humira/Eylea biosimilar revenue ramp, and which specialty biopharma navigates its niche commercial launch more efficiently.

Compare Avadel Pharmaceuticals and Innoviva by LUMRYZ narcolepsy once-nightly oxybate launch, Innoviva FTSE/Relvar royalty income, and which specialty pharmaceutical model — commercial launch vs royalty stream — is the better risk-adjusted investment.

Compare Insmed and Azenta by brensocatib bronchiectasis pivotal trial commercialization, cryogenic sample storage and genomics ARR, and which healthcare company has higher near-term earnings inflection from its flagship program.

Compare Tyler Technologies and its government software platform by ERP/civic/court software ARR, cloud migration revenue, and how niche vertical SaaS platforms serving government clients earn above-average revenue retention vs commercial SaaS peers.

Compare Apellis Pharmaceuticals and rare disease biotech by Syfovre geographic atrophy launch revenue, pegcetacoplan nephrology expansion, and which complement pathway-targeting biotech reaches sustainable commercial revenue first.

Compare Amedisys and LHC Group by Medicare-certified home health visit volume, hospice admission growth, PDGM reimbursement impact, and how the consolidation of the home health sector through M&A reshapes competitive positioning for the two largest independent operators.

Compare STAAR Surgical and Allegiant Travel by EVO ICL vision correction procedure global volume growth, Las Vegas-focused ULCC leisure route profitability, ancillary revenue ARPU, and which small-cap consumer discretionary company has more durable secular revenue growth.

Compare Intuitive Surgical and Abbott Laboratories by surgical robotics, medical devices, AI integration, recurring revenue, margins, and long-term medtech growth.

Compare Eli Lilly and AbbVie by GLP-1 drug dominance, pipeline strength, revenue growth, dividend yield, valuation, and which pharmaceutical stock offers better value.

Compare Incyte and AbbVie by Opzelura growth, Skyrizi and Rinvoq momentum, Humira biosimilar transition, and biopharma investment.

Compare Beam Therapeutics and CRISPR Therapeutics by gene editing technology, clinical progress, Casgevy approval, and genetic medicine investing.

Compare Sangamo Therapeutics and CRISPR Therapeutics by gene editing platform, clinical pipeline, partnership revenue, and genetic medicine investment.

Compare Ultragenyx Pharmaceutical and Alnylam by rare disease platforms, pipeline depth, ATTR amyloidosis market, and biotech investment.

Compare bluebird bio and CRISPR Therapeutics by sickle cell treatment, Lyfgenia vs Casgevy, financial strength, and genetic medicine investing.

Compare Smith & Nephew and Zimmer Biomet by robotic surgery adoption, CORI vs ROSA platforms, wound management revenue, and orthopedic medtech investment.

Compare Kenvue and P&G by brand portfolio quality, dividend track record, pricing power, and consumer staples investment.